The Trump administration is trading billions of dollars of taxpayer money for ownership stakes in companies. The unusual practice shows no sign of slowing.
Category: Regulation and Deregulation of Industry
-
Boeing Tackles Quality With a ‘War on Defects’
Two years after a panel flew off a 737 Max, Boeing is doing more inspections, completing work in its intended order and making other changes. Can the company keep it up?
-
Consumer Bureau’s Bank Examiners Criticize New ‘Humility Pledge’
The Consumer Financial Protection Bureau said it would require a vow to “work collaboratively” with companies before beginning a review.
-
Thousands of French Brands Sue Shein, Accusing It of Unfair Competition
The class-action lawsuit is the latest push against the Chinese retailer in France, where protests outside its first store broke out earlier this month.
-
Top Fed Official Boosts Odds of a December Rate Cut
John C. Williams, president of the Federal Reserve Bank of New York, said the central bank had scope to lower borrowing costs ‘in the near term.’
-
Botulism Bacteria Found in Infant Formula, ByHeart Confirms
ByHeart, the maker of the product, has been linked to an outbreak of illnesses among infants that led to their hospitalizations.
-
After Shutdown, Labor Department Says Some Data is Gone for Good
Surveys were delayed and some cannot be collected at all, officials said, further complicating the Federal Reserve’s decision on interest rates next month.
-
The Fed Is Cutting Bank Oversight. Critics See Risks.
The regulator is cutting staff and easing oversight in ways that critics say might make supervisors less equipped to spot a crisis in advance, risking deeper damage to the economy.
-
A Pill for Women’s Libido Meets a Cultural Moment
A decade ago, Cindy Eckert struggled to convince skeptics about a drug for premenopausal women. Lately, her business is booming.
-
F.D.A. Sharply Limits Use of Drug Linked to Two Teen Deaths
A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.